Quoin Pharmaceuticals financials
$4.88−7.22%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$5.5M | -$5.1M | -$4.5M | -$4.0M | -$3.8M | -$4.0M | -$2.4M | -$2.5M | -$2.1M | -$2.5M | -$2.2M | -$2.1M |
| Net income | -$5.4M | -$5.0M | -$4.3M | -$3.9M | -$3.7M | -$3.8M | -$2.3M | -$2.3M | -$2.0M | -$2.3M | -$2.0M | -$1.9M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-1.90 | $-1.77 | $-1.73 | $-6.71 | $-6.28 | $-6.50 | $-12.96 | $-16.29 | $-13.68 | $-38.73 | $-72.32 | $-68.25 |
| EBITDA | -$5.4M | -$5.1M | -$4.5M | -$4.0M | -$3.8M | -$3.9M | -$2.4M | -$2.5M | -$2.1M | -$2.4M | -$2.2M | -$2.1M |
| Operating cash flow | -$3.1M | -$4.9M | -$5.0M | -$2.2M | -$3.7M | -$2.6M | -$2.2M | -$2.2M | -$2.0M | -$1.4M | -$3.2M | -$1.3M |
| Free cash flow | -$3.1M | -$4.9M | -$5.0M | -$2.2M | -$3.7M | -$2.6M | -$2.2M | -$2.2M | -$2.0M | -$1.4M | -$3.2M | -$1.3M |
| Diluted shares | 2.8M | 2.8M | 2.5M | 0.6M | 0.6M | 0.6M | 0.2M | 0.1M | 0.1M | 0.1M | 0.0M | 0.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.8M | $3.1M | $3.8M | $1.8M | $1.7M | $3.8M |
| Short-term investments | $7.0M | $10.9M | $14.9M | $3.6M | $6.1M | $7.7M |
| Total debt | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M |
| Total assets | $12.0M | $15.7M | $20.4M | $6.4M | $8.9M | $13.0M |
| Total liabilities | $8.0M | $6.9M | $7.3M | $7.6M | $6.4M | $7.0M |
| Shareholders' equity | $3.9M | $8.8M | $13.1M | -$1.2M | $2.6M | $5.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology